Fluconazole

REFERENCES

• Anaissie E., Bodey G.P. Noscomial fungal infections. Old problems and new challenges. Infectious Disease Clinics of North America 1989; 3: 867–882
   PubMedGoogle Scholar
• Anaissie E., Kantarjian H., Ro J., Hopfer R., Rolston K., Fainstein V., Bodey G. The emerging role of Fusarium infections in patients with cancer. Medicine 1988; 67: 77–83
   PubMed Web of Science ®Google Scholar
• Andriole V.T., Miniter P., George D., Kordick D., Patterson T.F. Animal models: Their usefulness for studies of fungal pathogenesis and drug efficacy in aspergillosis. Reviews of Infectious Diseases 1992, in press
   Google Scholar
• Benard G., Bueno J.P., Yamashiro-Kanashiro E.H., Shikanai-Yasuda M.A., DelNegro G.M., Melo N.T., Sato M.N., Amato Neto V., Shiroma M., Duarte A.J.S. Paracoccidioidomycosis in a patient with HIV infection: immunological study. Transactions of the Royal Society of Tropical Medicine and Hygiene 1990; 84: 151–152
   PubMed Web of Science ®Google Scholar
• Bennett J.E. Flucytosine. Annals of Internal Medicine 1977; 86: 319–322
   PubMed Web of Science ®Google Scholar
• Bennett J.E. Fluconazole: a novel advance in therapy for systemic fungal infections [Overview]. Reviews of Infectious Diseases 1990; 12: S263–S389
   PubMedGoogle Scholar
• Bennett J.E., Dismukes W.E., Duma R.J., Medoff G., Sande M.A., Gallis H., Leonard J., Fields B.T., Bradshaw M., Haywood H., McGee Z.A., Cate T.R., Cobbs C.G., Warner J.F., Alling D.W. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. New England Journal of Medicine 1979; 301: 126–131
   PubMed Web of Science ®Google Scholar
• Bozzette S.A., Larsen R.A., Chiu J., Leal M.A.E., Jacobson J., Rothman P., Robinson P., Gilbert G., McCutchan J.A., Tilles J., Leedom J.M., Richman D.D. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. New England Journal of Medicine 1991; 324: 580–584
   PubMed Web of Science ®Google Scholar
• Christiansen K.J., Bernard E.M., Gold J.W.M., Armstrong D. Distribution and activity of amphotericin B in humans. Journal of Infectious Diseases 1985; 152: 1037–1043
   PubMed Web of Science ®Google Scholar
• Collette N., van der Auwera P., Lopez A.P., Heymans C., Meunier F. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrobial Agents and Chemotherapy 1989; 33: 362–368
   PubMed Web of Science ®Google Scholar
• Craven P.C., Graybill J.R., Jorgensen J.H., Dismukes W.E., Levine B.E. High-dose ketoconazole for treatment of fungal infections in the central nervous system. Annals of Internal Medicine 1983; 98: 160–167
   PubMed Web of Science ®Google Scholar
• Denning D.W., Tucker R.M., Hanson L.H., Stevens D.A. Treatment of invasive aspergillosis with itraconazole. American Journal of Medicine 1989; 86: 791–800
   PubMed Web of Science ®Google Scholar
• Dick J.D., Merz W.G., Saral R. Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrobial Agents and Chemotherapy 1980; 18: 158–163
   PubMed Web of Science ®Google Scholar
• Dismukes W.E. Cryptococcal meningitis in patients with AIDS. Journal of Infectious Diseases 1988; 157: 624–628
   PubMed Web of Science ®Google Scholar
• Dismukes W.E., Bennett J.E., Drutz D.J., Graybill J.R., Remington J.S., Stevens D.A. Criteria for evaluation of therapeutic response to antifungal drugs. Reviews of Infectious Diseases 1980; 2: 535–545
   PubMedGoogle Scholar
• Dismukes, W.E., Cloud, G., Gallis, H.A., Kerkering, T.M., Medoff, G., Craven, P.C., Kaplowitz, L.G., Fisher, J.F., Gregg, C.R., Bowles, C.A., et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. New England Journal of Medicine 1987; 317: 334–341
   PubMed Web of Science ®Google Scholar
• Eilard T., Alestig K., Wahlen P. Treatment of disseminated candidiasis with 5-fluorocytosine. Journal of Infectious Diseases 1974; 130: 155–159
   PubMed Web of Science ®Google Scholar
• Fainstein V., Bodey G.P., Elting L., Maksymiuk A., Keating M., McCredie K.B. Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients. Antimicrobial Agents and Chemotherapy 1987; 31: 11–15
   PubMed Web of Science ®Google Scholar
• Firkin F.C. Therapy of deep-seated fungal infections with 5-fluorocytosine. Australian and New Zealand Journal of Medicine 1974; 4: 462–467
   PubMedGoogle Scholar
• Graybill J.R. Histoplasmosis and AIDS. Journal of Infectious Diseases 1988; 158: 623–626
   PubMed Web of Science ®Google Scholar
• Graybill J.R., Stevens D.A., Galgiani J.N., Sugar A.M., Craven P.C., Gregg C., Huppert M., Cloud G., Dismukes W.E. Ketoconazole treatment of coccidioidal meningitis. Annals of the New York Academy of Sciences 1988; 544: 488–496
   PubMedGoogle Scholar
• Harder E.J., Hermans P.E. Treatment of fungal infections with flucytosine. Archives of Internal Medicine 1975; 135: 231–237
   PubMedGoogle Scholar
• Haron E., Feld R., Tuffnell P., Patterson B., Hasselback R., Matlow A. Hepatic candidiasis: an increasing problem in immunocompromised patients. American Journal of Medicine 1987; 83: 17–26
   PubMed Web of Science ®Google Scholar
• Hay R.J., Dupont B., Graybill J.R. First International Symposium on Itraconazole. Reviews of Infectious Diseases 1987; 9(Suppl. 1)S1–S152
   PubMedGoogle Scholar
• Holt R.J., Newman R.L. The antimycotic activity of 5-fluorocytosine. Journal of Clinical Pathology 1973; 26: 167–174
   PubMed Web of Science ®Google Scholar
• Komshian S.V., Uwaydah A.K., Sobel J.D., Crane L.R. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Reviews of Infectious Diseases 1989; 11: 379–390
   PubMedGoogle Scholar
• Kovacs, J.A., Kovacs, A.A., Polis, M., Wright, W.C., Gill, V.J., Tuazon, C.V., Gelmann, E.P., Lane, H.C., Longfield, R., Overturf, G., et al. Cryptococcosis in the acquired immunodeficiency syndrome. Annals of Internal Medicine 1985; 103: 533–538
   PubMed Web of Science ®Google Scholar
• National Institute of Allergy and Infectious Diseases Mycoses Study Group. Treatment of blastomycosis and histoplasmosis with ketoconazole. Results of a prospective randomized clinical trial. Annals of Internal Medicine 1985; 103: 861–872
   PubMed Web of Science ®Google Scholar
• Negroni R., Palmieri O., Koren F., Tiraboschi I.N., Galimberti R. Oral treatment of paracoccidioidomycosis and histoplasmosis with itraconazole in humans. Reviews of Infectious Diseases 1987; 9(Suppl. 1)S47–S50
   PubMedGoogle Scholar
• Negroni R., Robles A.M., Arechavala A., Tuculet M.A., Galimberti R. Ketoconazole in the treatment of paracoccidioidomycosis and histoplasmosis. Reviews of Infectious Diseases 1980; 2: 643–649
   PubMedGoogle Scholar
• Patterson T.F., George D., Miniter P., Andriole V.T. The role of fluconazole in the early treatment and prophylaxis of experimental invasive aspergillosis. Journal of Infectious Diseases 1991; 164: 575–580
   PubMed Web of Science ®Google Scholar
• Patterson T.E., Miniter P., Andriole V.T. Efficacy of fluconazole in experimental invasive aspergillosis. Reviews of Infectious Diseases 1990; 12(Suppl. 3)S281–S285
   PubMedGoogle Scholar
• Powderly W.G., Kobayashi G.S., Herzig G.P., Medoff G. Amphotericin B-resistant yeast infection in severely immunocompromised patients. American Journal of Medicine 1988; 84: 826–832
   PubMed Web of Science ®Google Scholar
• Restrepo A., Gomez I., Robledo J., Patiño M.M., Cano L.E. Itraconazole in the treatment of paracoccidioidomycosis: a preliminary report. Reviews of Infectious Diseases 1987; 9(Suppl. 1)S51–S56
   PubMedGoogle Scholar
• Restrepo A., Stevens D.A., Gomez I., Leiderman E., Angel R., Fuentes J., Arana A., Mejia G., Vanegas A.C., Robledo M. Ketoconazole: a new drug for the treatment of paracoccidioidomycosis. Reviews of Infectious Diseases 1980; 2: 633–642
   PubMedGoogle Scholar
• Saag M.S., Dismukes W.E. Azole antifungal agents: emphasis on new triazoles. Antimicrobial Agents and Chemotherapy 1988; 32: 1–8
   PubMed Web of Science ®Google Scholar
• Stern J.J., Hartman B.J., Sharkey P., Rowland V., Squires K.E., Murray H.W., Graybill J.R. Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients. American Journal of Medicine 1988; 85: 477–480
   PubMed Web of Science ®Google Scholar
• Stevens D.A. Miconazole in the treatment of systemic fungal infections. American Review of Respiratory Disease 1977; 116: 801–806
   PubMed Web of Science ®Google Scholar
• Sugar A.M., Alsip A.G., Galgiani J.N., Graybill J.R., Dismukes W.E., Cloud G.A., Craven P.C., Stevens D.A., NIAID Mycoses Study Group. Pharmacology and toxicity of high-dose ketoconazole. Antimicrobial Agents and Chemotherapy 1987; 31: 1874–1878
   PubMed Web of Science ®Google Scholar
• Sugar A.M., Saunders C. Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome. American Journal of Medicine 1988; 85: 481–489
   PubMed Web of Science ®Google Scholar
• Sugar A.M., Stern J.J., Dupont B. Overview: Treatment of cryptococcal meningitis. Reviews of Infectious Diseases 1990; 12(Suppl. 3)S338–S348
   PubMedGoogle Scholar
• Tassel D., Madoff M.A. Treatment of Candida sepsis and Cryptococcus meningitis with 5-fluorocytosine. A new antifungal agent. JAMA 1968; 206: 830–832
   PubMed Web of Science ®Google Scholar
• Tucker R.M., Galgiani J.N., Denning D.W., Hanson L.H., Graybill J.R., Sharkey K., Eckman M.R., Satemi G., Libke R., Klein R.A., Stevens D.A. Treatment of coccidioidal meningitis with fluconazole. Reviews of Infectious Diseases 1990; 12(Suppl. 3)S380–S389
   PubMedGoogle Scholar
• Tucker R.M., Williams P.L., Arathoon E.G., Levine B.E., Harlstein H.I., Hanson L.H., Stevens D.A. Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis. Antimicrobial Agents and Chemotherapy 1988; 32: 369–373
   PubMed Web of Science ®Google Scholar
• Walsh T.J., Melcher G.P., Rinaldi M.G., Lecciones J., McGough D.A., Kelly P., Lee J., Callender D., Rubin M., Pizzo P.A. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. Journal of Clinical Microbiology 1990; 28: 1616–1622
   PubMed Web of Science ®Google Scholar
• Walsh T.J., Pizzo A. Treatment of systemic fungal infections: recent progress and current problems. European Journal of Clinical Microbiology and Infectious Diseases 1988; 7: 460–475
   PubMed Web of Science ®Google Scholar
• Walsh T.J., Rubin M., Hathorn J., Gress J., Thaler M., Skelton J., McKnight J., Browne M., Marshall D., Cotton D., Hiemenz J., Longo D., Wesley R., Pizzo P.A. Amphotericin-B versus high-dose ketoconazole for empirical antifungal therapy among febrile granulocytopenic cancer patients: a prospective randomized study. Archives of Internal Medicine 1991; 151: 765–770
   PubMed Web of Science ®Google Scholar
• Wingard J.R., Vaughan W.P., Braine H.G., Merz W.G., Saral R. Prevention of fungal sepsis in patients with prolonged neutropenia: a randomized double-blind placebo-controlled trial of intravenous miconazole. American Journal of Medicine 1987; 83: 1103–1110
   PubMed Web of Science ®Google Scholar
• Zuger A., Louie E., Holzman R.S., Simberkoff M.S., Rahal J.J. Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome. Annals of Internal Medicine 1986; 104: 234–240
   PubMed Web of Science ®Google Scholar